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Abstract. 
 
Major histocompatibility complex class II 
molecules are synthesized as a nonameric complex con-
sisting of three 
 
ab
 
 dimers associated with a trimer of in-
variant (Ii) chains. After exiting the TGN, a targeting 
signal in the Ii chain cytoplasmic domain directs the 
complex to endosomes where Ii chain is proteolytically 
processed and removed, allowing class II molecules to 
bind antigenic peptides before reaching the cell surface. 
Ii chain dissociation and peptide binding are thought to 
occur in one or more postendosomal sites related either 
to endosomes (designated CIIV) or to lysosomes (des-
ignated MIIC). We now find that in addition to initially 
targeting 
 
ab
 
 dimers to endosomes, Ii chain regulates 
the subsequent transport of class II molecules. Under 
normal conditions, murine A20 B cells transport all of 
their newly synthesized class II I-A
 
b
 
 
 
ab
 
 dimers to the 
plasma membrane with little if any reaching lysosomal 
compartments. Inhibition of Ii processing by the cys-
teine/serine protease inhibitor leupeptin, however, 
blocked transport to the cell surface and caused a dra-
matic but selective accumulation of I-A
 
b
 
 class II mole-
cules in lysosomes. In leupeptin, I-A
 
b
 
 dimers formed 
stable complexes with a 10-kD NH
 
2
 
-terminal Ii chain 
fragment (Ii-p10), normally a transient intermediate in 
Ii chain processing. Upon removal of leupeptin, Ii-p10 
was degraded and released, I-A
 
b
 
 dimers bound anti-
genic peptides, and the peptide-loaded dimers were 
transported slowly from lysosomes to the plasma mem-
brane. Our results suggest that alterations in the rate or 
efficiency of Ii chain processing can alter the postendo-
somal sorting of class II molecules, resulting in the in-
creased accumulation of 
 
ab
 
 dimers in lysosome-like 
MIIC. Thus, simple differences in Ii chain processing 
may account for the highly variable amounts of class II 
found in lysosomal compartments of different cell types 
or at different developmental stages.
 
T
 
he
 
 initiation of most immune responses requires
antigen recognition by helper T lymphocytes. The
antigen receptors on T cells can only recognize anti-
gens as small peptides bound to major histocompatibility
complex (MHC)
 
1
 
 class II molecules at the surface of anti-
gen presenting cells (Cresswell, 1994; Germain, 1994). The
complexes between class II molecules and antigenic pep-
tides are formed intracellularly somewhere along the en-
docytic pathway (Germain, 1994; Wolf and Ploegh, 1995).
This process requires the internalization of protein antigen
and its delivery to a site suitable for the generation of anti-
genic peptides. In addition, the peptides must be gener-
ated within, or transferred to, a site to which newly synthe-
sized MHC class II molecules are delivered and rendered
competent for peptide binding (Davidson et al., 1991).
Invariant (Ii) chain plays a central role in controlling the
intracellular transport of MHC class II (Cresswell, 1996).
In the ER, Ii chain is synthesized as a trimer that com-
plexes with three 
 
ab
 
 dimers of MHC class II (Roche et al.,
1991). Its NH
 
2
 
-terminal cytoplasmic domain contains a well-
known targeting signal that directs class II–Ii chain com-
plexes to endosomes after exit from the TGN (Bakke and
Dobberstein, 1990; Lotteau et al., 1990; Neefjes et al., 1990;
Odorizzi et al., 1994; Pieters et al., 1993). Once in endo-
somes, Ii chain is subjected to proteolysis by acid hydro-
lases (Roche and Cresswell, 1991). Degradation occurs in
a stepwise fashion, resulting in the appearance of class II–
bound NH
 
2
 
-terminal intermediates containing the Ii chain
cytoplasmic domain, membrane anchor, and parts of its lu-
minal domain (Newcomb and Cresswell, 1993). The inter-
mediates accumulate in the presence of protease inhibitors
that interfere with Ii chain processing such as the serine-
cysteine protease inhibitor leupeptin, treatment with which
can also block the transport of at least some class II haplo-
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types to the cell surface (Amigorena et al., 1995; Blum and
Cresswell, 1988; Neefjes and Ploegh, 1992). How leupeptin
inhibits surface appearance is unknown.
In human cells, Ii chain degradation intermediates in-
clude a 21–22-kD fragment (designated LIP [leupeptin-
inducible peptide]) and a 10–12-kD fragment (designated
SLIP [small leupeptin-inducible peptide]) (Blum and Cress-
well, 1988; Maric et al., 1994). In murine cells, only a 10–
12-kD fragment has been identified (Ii-p10) (Amigorena
et al., 1995). Ii-p10 remains as a trimer associated with
three 
 
ab
 
 dimers and blocks the binding of antigenic pep-
tides (Amigorena et al., 1995; Morton et al., 1995). It is
thus likely that Ii-p10 includes a luminal region of Ii chain
(designated CLIP) known to occupy the peptide binding
groove of 
 
ab
 
 dimers. Cleavage of Ii-p10 by a leupeptin-
sensitive protease causes its dissociation from 
 
ab
 
 dimers,
while leaving CLIP in the peptide binding groove. The re-
moval of CLIP is favored at acidic pH but is additionally
catalyzed by a second MHC gene product, HLA-DM (Sloan
et al., 1995; Denzin and Cresswell, 1995; Karlsson et al.,
1994; Roche, 1995). In mutant cells lacking HLA-DM, there
is defective loading of antigenic peptides and the appear-
ance of CLIP-
 
ab
 
 dimers on the plasma membrane (Mel-
lins et al., 1994; Riberdy et al., 1992).
The precise site(s) where these events occur remains un-
clear. In A20 B cells, a specialized population of endo-
some-like vesicles designated CIIV (for class II vesicles)
represents a site through which a majority of newly syn-
thesized class II molecules pass en route to the cell surface
and a place where antigenic peptides bind 
 
ab
 
 dimers of
the I-A
 
d
 
 haplotype (Amigorena et al., 1994, 1995; Barnes
and Mitchell, 1995). CIIV are physically distinct from the
bulk of endosomes and lysosomes and contain at least
some HLA-DM (Pierre et al., 1996). Despite the fact that
most of the 
 
ab
 
 dimers reaching CIIV are newly synthe-
sized, CIIV contain little or no intact Ii chain (Amigorena
et al., 1995). Thus, Ii chain–
 
ab
 
 complexes first may be de-
livered to endosomes where Ii chain is cleaved before be-
ing delivered to CIIV. That peptide loading can occur in
CIIV has been demonstrated by experiments showing that
leupeptin causes CIIV to transiently accumulate Ii-p10–
containing complexes, which can then bind peptide (Ami-
gorena et al., 1995).
In human Epstein-Barr virus–transformed B lymphoblasts,
most class II molecules have been localized to structures
collectively designated MIIC (for MHC class II compart-
ment) (Peters et al., 1991; Tulp et al., 1994; West et al.,
1994). MIICs differ from CIIVs in that the latter contain en-
dosomal but not lysosomal markers, while MIICs have
most or all of the features of lysosomes (Peters et al., 1991,
1995; Pierre et al., 1996). Interestingly, the distribution of
class II between endosomal (CIIV) and lysosomal (MIIC)
compartments varies widely among cell types. Since lyso-
somes are classically defined as terminal degradative or-
ganelles (Kornfeld and Mellman, 1989), such variations
may reflect differences in the rates at which class II is
turned over in different cell types. On the other hand,
MIICs also contain the bulk of HLA-DM and can host the
loading of antigenic peptides onto class II molecules (Sander-
son et al., 1994). The extent to which these complexes es-
cape degradation and reach the cell surface is unclear. Nor
is it at all clear how different cell types regulate the intra-
cellular distribution of class II molecules between early
and late endocytic compartments.
We now show that murine A20 cells expressing endog-
enous I-A
 
d
 
 and transfected I-A
 
b
 
 normally localize little
class II in lysosomes. Selective lysosomal accumulation of
I-A
 
b
 
 
 
ab
 
 dimers can be induced after leupeptin treatment.
Interestingly, I-A
 
b
 
 dimers, but not I-A
 
d
 
 dimers, are in-
duced by leupeptin to form stable complexes with Ii-p10.
Upon removal of the inhibitor, the Ii-p10 was removed
and class II molecules were slowly transported from lyso-
somes to the cell surface. Thus, the rate of dissociation of
Ii chain intermediates can regulate whether newly synthe-
sized class II molecules are transported to the plasma
membrane or to lysosomes.
 
Materials and Methods
 
Cells and Antibodies
 
All experiments were performed using A20 B lymphoma cell line trans-
fected with a cDNA encoding I-A
 
b
 
 class II molecules (B4-14 cells; kindly
provided by Avlin Barlow and Charles Janeway, Yale University, New
Haven, CT). The antibodies used for these experiments were: mouse anti–
mouse I-A
 
b
 
 mAb Y3P (Janeway et al., 1984), anti–mouse I-A
 
d
 
 mAb MKD6
(Braunstein et al., 1990), rat anti–mouse lgp-B/lamp-2 mAb GL2A7
(Granger et al., 1990), hamster anti–mouse Ii chain mAb IN1 (directed
against the Ii chain cytoplasmic tail) (Peterson and Miller, 1990), FITC-
conjugated rat anti–mouse transferrin receptor CD71 (Pharmingen, San Di-
ego, CA), a rat mAb reactive against both I-A
 
b
 
 and I-A
 
d
 
 mouse MHC class
II molecules (M5.114) (Bhattacharya et al., 1981), and a polyclonal rabbit
serum against the conserved cytoplasmic tail of mouse I-A 
 
b
 
 chain.
 
Pulse-Chase Labeling
 
The experiments were performed as previously described (Amigorena
et al., 1994). Briefly, the cells were metabolically labeled for 20 min with
[
 
35
 
S]methionine/cysteine labeling mix (500 
 
m
 
Ci/ml; Amersham Corp., Ar-
lington Heights, IL) and chased for various periods of time. Leupeptin
treatments were performed by adding 2 mM leupeptin (Sigma Chemical
Co., St. Louis, MO) to the labeling and the chase media.
 
Cell Surface Biotinylation and Immunoprecipitation
 
Cell surface biotinylation was performed as previously described (Amig-
orena et al., 1994). Cells were biotinylated with NHS-SS-biotin (Pierce
Chemical Co., Rockford, IL) and lysed in detergent, and I-A
 
b
 
 class II mol-
ecules were precipitated with Y3P-coated protein A–Sepharose beads
(Pharmacia Fine Chemicals, Piscataway, NJ). I-A
 
b
 
 molecules were eluted
by a 30-min incubation at room temperature in 100 
 
m
 
l PBS containing 2%
SDS. 80 
 
m
 
l was then used to recover the biotinylated surface proteins by
adsorption to streptavidin-agarose (Bio Rad Laboratories, Hercules, CA).
After washing, the beads were resuspended in 20 
 
m
 
l of sample buffer con-
taining 0.5 M DTT and incubated for 30 min at room temperature (this
treatment releases SDS-stable complexes from the beads without boiling
and thus permits the visualization of the different conformational forms of
class II molecules accessible to biotinylation at the cell surface). Parallel
samples were boiled for 3 min before analysis on 12% acrylamide gels. Af-
ter scanning the autoradiographs with a video camera (Bio print system;
Vilber Lourmat, Marne-La-Vallée, France), the quantifications were per-
formed using the Bio-1D software (Vilber Lourmat).
 
Free Flow Electrophoresis
 
Free flow electrophoresis (FFE) fractionation was performed as previ-
ously described (Amigorena et al., 1994). Briefly, after homogenization in
a ball-bearing homogenizer, the postnuclear supernatant was first frac-
tionated by flotation in a discontinous sucrose gradient. The low density
membranes were then further fractionated by FFE using a modified
Bender and Hobein Elphor VaP 21/22 or Octypus PZE (Dr. Weber,
GmbH, Munich, Germany). Membranes in individual or pooled fractions
were pelleted and lysed before immunoprecipitation. 
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Percoll Gradient Centrifugation
 
Percoll gradients were performed as described (Pierre et al., 1996). Briefly,
the cells were washed twice and homogenized in a ball-bearing homoge-
nizer. The resulting postnuclear supernatant was fractionated by centrifu-
gation in a 25% Percoll gradient at 4
 
8
 
C for 45 min at 18,000 rpm in a 70.1
Ti rotor (Beckman Instruments, Inc., Palo Alto, CA). 1-ml fractions were
collected. Endosomes were labeled before fractionation by incubating the
cells for 30 min at 37
 
8
 
C in RPMI medium containing 35 
 
m
 
g/ml HRP-conju-
gated human transferrin (Pierce Chemical Co.); 50 
 
m
 
l of each fraction was
mixed with 50 
 
m
 
l of PBS containing 0.1% TX-100, and HRP acivity was
detected using 
 
o
 
-phenylenediamine dihydrochloride (OPD; Sigma Chem-
ical Co.). After 1:10 dilution, the membranes were pelleted by centrifuga-
tion and lysed before class II molecules or Ii chain were immunoprecipi-
tated as described above.
 
Immunofluorescence Staining and Confocal Microscopy
 
Immunofluorescence was performed as previously described (Bonnerot et
al., 1995). Briefly, cells were allowed to adhere on glass coverslips pre-
coated with 0.2% poly-
 
l
 
-lysine, were fixed for 10 min in PBS containing
3% paraformaldehyde, and were permeabilized with 0.05% saponin in
PBS. The cells were then incubated for 30 min with primary antibodies in
PBS with 0.2% BSA and 0.05% saponin. After three washes, the cells were
stained with FITC- or TRITC-conjugated streptavidin, F(ab
 
9
 
)
 
2
 
 fragments
of donkey anti–rat IgG, donkey anti–mouse IgG, or donkey anti–rabbit
IgG antisera for 30 min. The coverslips were then mounted in Mowiol
(Calbiochem-Novabiochem Corp., La Jolla, CA). Immunofluorescence
microscopy was performed using a TCS scanning laser confocal micro-
scope (Leica Microscopy and Scientific Instruments, Inc., Heerbrugg,
Switzerland).
 
Immunoelectron Microscopy
 
Control cells and cells treated with 2 mM leupeptin for 16 h were fixed in
2% paraformaldehyde in 0.2 M phosphate buffer, pH 7.4, for 1 h at room
temperature and processed for ultracryomicrotomy as described (Liou et al.,
1996; Kleijmeer et al., 1996). For the visualization of MHC class II molecules,
ultrathin cryosections were immunolabeled with the rat mAb M5.114 fol-
lowed by a rabbit polyclonal directed against rat IgG. Double labelings al-
lowing the detection of lysosomal glycoprotein (lgp)–B/lysosome-associ-
ated membrane protein (lamp)–2 and MHC class II or Ii chain and MHC
class II were performed with the rat monoclonal GL2A7 directed against
lgp-B, the hamster monoclonal IN1 antibody directed against the cytoplas-
mic domain of the Ii chain, and a rabbit polyclonal antibody raised against
the cytoplasmic domain of the I-A molecule. All the antibodies were visu-
alized with protein A–gold conjugates (purchased from J.W. Slot, Utrecht
University, The Netherlands). Ultrathin cryosections were performed with a
Leica FCS (Leica Microscopy and Scientific Instruments, Inc.) ultracryo-
microtome and analyzed with a CM120 electron microscope (Philipps
Electronic Instruments, Inc., Mahwah, NJ).
 
Results
 
Leupeptin Blocks I-A
 
b
 
 Transport to the
Cell Surface and Causes the Stable Association
of 
 
ab
 
 
 
Dimers with Ii-p10
 
Treatment of A20 cells with the protease inhibitor leupep-
tin increases the fraction of endogenous I-A
 
d
 
 class II mole-
cules normally found in a complex with the 10-kD Ii chain
fragment Ii-p10 (Amigorena et al., 1995). The increase in
I-A
 
d
 
–Ii-p10 complexes was transient, however, since even
in the continued presence of leupeptin Ii-p10 was released
and followed by the transport of peptide-loaded I-A
 
d
 
 
 
ab
 
dimers to the cell surface. Since 
 
ab
 
 dimers of the I-A
 
b
 
 hap-
lotype may have a higher affinity for Ii chain than I-A
 
d
 
dimers (Sette et al., 1995), we asked whether leupeptin might
more severely affect the processing and transport of class
II molecules in A20 cells expressing I-A
 
b
 
 
 
ab
 
 dimers.
A20 cells stably transfected with cDNAs encoding I-A
 
b
 
a
 
 and 
 
b
 
 chains were metabolically labeled for 20 min and
chased for various times before lysis and immunoprecipi-
tation of class II with the mAb Y3P. Immunoprecipitates
were analyzed by SDS-PAGE without boiling to deter-
mine if the class II molecules had bound antigenic peptide,
an event that renders some 
 
ab
 
 dimers stable to SDS at
room temperature, resulting in their migration as a 60-kD
complex (“compact dimer”) (Germain and Hendrix, 1991).
As shown in Fig. 1 
 
A
 
 (
 
left
 
), control cells began to accu-
mulate SDS-stable I-A
 
b
 
 compact dimers (“
 
C
 
”) within 60
min of chase. The amount of the 60-kD dimer reached a
plateau by 120 min and remained constant, accounting for
 
z
 
90% of the transfected I-A
 
b
 
 recovered from these cells.
This is in contrast with the endogenous 
 
ab
 
 dimers of the
I-A
 
d
 
 haplotype, a much smaller fraction of which (15%)
can be rendered SDS stable by peptide binding (Germain
and Hendrix, 1991; Amigorena et al., 1995). Little class II
was immunoprecipitated at time points 
 
,
 
60 min since the
antibody used (Y3P) does not detect class II molecules
bound to intact Ii chain. Using a polyclonal antibody that
detects all forms of class II, equivalent recovery of class II
was found at all chase times, indicating that there was no
degradation during the chase period (0–240 min; not
shown).
A strikingly different result was obtained in cells labeled
in the presence of leupeptin. As shown in Fig. 1 
 
A
 
 (
 
right
 
),
leupeptin strongly inhibited the formation of 60-kD pep-
tide-loaded, SDS-stable dimers and, instead, induced the
accumulation of a 70-kD band (p70); a band of the same
molecular mass appeared transiently in control cells (60–
120 min). Leupeptin also enhanced the accumulation of a
small amount of Ii-p10.
To better characterize the species induced by leupeptin,
their mobilities were compared by SDS-PAGE with and
without boiling before electrophoresis. As shown in Fig.
1 
 
B
 
, the 60-kD SDS-stable compact dimer in control cells
was, as expected, converted into 
 
z
 
30-kD 
 
a
 
 and 
 
b
 
 mono-
mers. In leupeptin-treated cells, the 70-kD band yielded
not only the 
 
a
 
 and 
 
b
 
 chains but also Ii-p10, suggesting that
Ii-p10 had formed a stable complex with the 
 
ab
 
 dimers.
This was confirmed by immunoprecipitation of the leupep-
tin lysates using an mAb to the Ii chain cytoplasmic tail
(IN-1). As shown in Fig. 1 
 
C
 
, precipitation with IN-1 re-
sulted in the recovery of Ii-p10, p70, and associated 
 
a
 
 and
 
b
 
 chains (Fig. 1 
 
C
 
). As expected, intact Ii chain was also
precipitated under these conditions. Therefore, p70 repre-
sents an SDS-stable, ternary complex of I-A
 
b
 
 
 
ab
 
 dimers
together with Ii-p10. Since in I-A
 
b
 
, 
 
ab
 
 dimers bound to
CLIP, but not to intact Ii chain, are also SDS stable (Miya-
zaki et al., 1996), Ii chain cleavage appears to induce a con-
formational change that confers SDS stability to the com-
plex.
Although leupeptin was previously found to induce the
transient accumulation of Ii-p10 in A20 cells expressing
only class II of the I-A
 
d
 
 haplotype, the degree to which this
Ii chain fragment was induced in I-A
 
b
 
–expressing cells was
more pronounced. To directly compare the ability of both
haplotypes to complex with Ii-p10, A20 cells expressing I-A
 
d
 
ab
 
 dimers with or without I-A
 
b
 
 
 
ab
 
 dimers were pulse la-
beled and chased for various periods of time in the pres-
ence or absence of leupeptin, and then class II complexes
were precipitated using mAbs specific for one or the other 
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haplotypes. As shown in Fig. 1 
 
D
 
, and as found previously,
Ii-p10 bound to I-A
 
d
 
 
 
ab
 
 dimers could be coprecipitated
only transiently, with a peak at 1 h of chase. In contrast, in
the I-A
 
b
 
–expressing cells, the amount of Ii-p10 recovered
that bound to class II molecules increased steadily through-
out the chase period. Thus, Ii-p10 formed a more stable
complex with I-A
 
b
 
 than with I-A
 
d
 
 
 
ab
 
 dimers. This would
account for why the Ii-p10–
 
ab
 
 complex (p70) was barely
detected in cells expressing only I-A
 
d
 
 (Amigorena et al.,
1995).
We showed previously that leupeptin delayed the cell
surface delivery of I-A
 
d
 
 
 
ab
 
 dimers by 1–2 h (Amigorena et
al., 1995). If association with Ii-p10 was responsible for re-
taining class II molecules intracellularly, the more stable
association of I-A
 
b
 
 dimers with Ii-p10 suggested that leu-
peptin might more severely delay their delivery to the
plasma membrane. To address this question, transfected
A20 cells were pulse labeled, and then chased with or
without leupeptin for various periods of time. At various
intervals, class II molecules that had reached the surface
were detected by derivatization with NHS-SS-biotin and
total vs surface class II determined by immunoprecipita-
tion.
In the absence of leupeptin, both SDS-stable and unsta-
ble I-A
 
b
 
 class II molecules rapidly formed SDS-stable
compact dimers (“C”) that were efficiently transported to
the cell surface after a lag of just 1–2 h (Fig. 2, top). These
kinetics were similar to those previously observed for I-Ad
class II molecules (Amigorena et al., 1995). In the pres-
ence of leupeptin, most of the class II molecules recovered
Figure 1. Leupeptin induces
an accumulation of SDS-
resistant I-Ab Ii-p10 com-
plexes. (A) Leupeptin in-
duces the accumulation of
10-kD (Ii-p10) and 70-kD
(p70) proteins that coprecipi-
tate with I-Ab. I-Ab–express-
ing A20 cells were pulsed for
20 min with [35S]methionine
and chased at 378C for the in-
dicated times in the presence
or absence of 2 mM leupep-
tin. After lysis, the I-Ab mol-
ecules were immunoprecipi-
tated using the Y3P mAb.
The samples were not boiled
before SDS-PAGE. Labeled
class II molecules were not
detected before 30 min of
chase because the Y3P mAb
used for immunoprecipita-
tion does not detect imma-
ture ab dimers complexed
with intact Ii chain. (B) p70
represents SDS-stable com-
plexes containing class II a
and b chains and a 10-kD
protein. After a 20-min
pulse and 4-h chase with or
without 2 mM leupeptin
(lanes  Lp and C, respec-
tively), class II molecules
were immunoprecipitated us-
ing the Y3P mAb, and the
samples were boiled (B) or
not boiled (NB) before SDS-
PAGE. After boiling, p70
dissociated quantitatively
into monomers correspond-
ing to ab and Ii-p10. (C) p70
represents SDS-stable I-Ab
ab–Ii-p10 complexes. After a 20-min pulse and 4-h chase in the presence of leupeptin, class II molecules were immunoprecipitated with
either anti–I-Ab (Y3P) or anti–Ii chain cytoplasmic domain (IN-1) mAbs. While both antibodies precipitated the p70 complex, only
anti–class II mAb precipitated the 60-kD SDS-stable compact dimer. Thus, p70 but not compact dimers are complexed with Ii chain or
Ii chain fragments (i.e., Ii-p10) that contain the Ii chain cytoplasmic domain. (D) Kinetics of association between Ii-p10 and I-Ab or
I-Ad. Pulse-chase experiments were performed as above using A20 cells expressing only I-Ad or expressing both I-Ad and I-Ab. I-Ad
or I-Ab–containing complexes were then immunoprecipitated using specific mAbs (Y3P and MKD6, respectively), and the amounts of
Ii-p10 associated to the class II molecules were quantified by phosphorimaging. The association of Ii-p10 with I-Ab persisted through-
out the chase period, while Ii-p10–I-Ad complexes appeared only transiently.Brachet et al. Transport of Class II Molecules to and from Lysosomes 55
Figure 2. Intracellular retention of Ii-p10–associated class II mol-
ecules. Cells were pulsed for 20 min and chased for the indicated
times (h) in the presence or absence of 2 mM leupeptin. At each
time point, the cells were surface biotinylated before lysis. Total
and cell surface biotinylated class II molecules were sequentially
immunoprecipitated using the mAb Y3P and streptavidin-agarose.
The samples were then analyzed by SDS-PAGE without boiling
before electrophoresis. In untreated control cells (top), peptide-
loaded, 60-kD compact ab dimers (“C”) began to appear both
in total lysates and on the surface after 0.5 h of chase. A small
amount of the p70 complex of Ii-p10–ab dimers appeared tran-
siently, beginning also at 0.5 h of chase. In leupeptin-treated cells
(bottom), p70 began to accumulate in total lysates by 0.5 h, but
little was recovered at the plasma membrane. Peptide-loaded
compact dimers only began to appear after 2–4 h of chase both in
lysates and at the cell surface.
Figure 3. Fractionation of leupeptin-treated A20 cells by free
flow electrophoresis. (A) A20 cells were pulse labeled for 20 min
and chased for 2 h in the presence of leupeptin before fraction-
ation by FFE. Membranes collected in each fraction were pel-
leted by centrifugation and lysed in Triton X-100, and I-Ab class
II molecules were immunoprecipitated using mAb MKD6. The
samples were then analyzed by SDS-PAGE without boiling. The
positions of compact dimers (“C”), a, b chains, Ii-p10, and a p12
protein of unknown origin are indicated relative to the positions
of markers for the major protein peak (plasma membrane), endo-
somes/lysosomes (b-hexosaminidase), and anodally shifted CIIV-
containing fractions. (Left) Anode; (right) cathode. (B) I-Ab–
expressing A20 cells were pulse labeled for 20 min and chased for
4 h in the presence of leupeptin before fractionation by FFE. The
positions of p70 (Ii-p10–ab complexes), 60-kD peptide-loaded
compact dimers, free a and b chains, and Ii-p10 are indicated.
(C) Positions of marker enzymes for plasma membrane (alkaline
phosphodiesterase) and endosomes/lysosomes (b-hexosaminidase)
in the FFE profile shown in B. p70 codistributed largely with the
lysosomal marker b-hexosaminidase.The Journal of Cell Biology, Volume 137, 1997 56
as 70-kD Ii-p10 complexes (p70) failed to reach the cell
surface even after 4 h of chase (Fig. 2, bottom). A small
amount of SDS-stable, peptide-loaded compact dimers did
begin to appear after 2–4 h and were selectively trans-
ported to the plasma membrane. Thus, association of Ii-
p10 with ab dimers correlated with, and was probably re-
sponsible for, the intracellular retention of MHC class II
molecules. Leupeptin did not affect the transport of class
II molecules that were not bound to Ii-p10, indicating that
the protease inhibitor did not inhibit MHC class II trans-
port pathway per se. The kinetics of transport to the sur-
face of membrane IgG was not affected by leupeptin (not
shown), further indicating that the transport block was
specific to the subset of class II molecules complexed with
Ii-p10.
Ii-p10 Complexes of I-Ab Dimers Reach but Do Not 
Accumulate in CIIV
We previously found that in leupeptin-treated A20 cells,
complexes of Ii-p10 and I-Ad dimers selectively accumu-
lated in CIIV, a vesicle population that can be resolved from
all other intracellular organelles by FFE (Amigorena et al.,
1995). The intracellular sites of accumulation of I-Ad and
I-Ab were compared by fractionating leupeptin-treated
cells using FFE. The distribution of I-Ad molecules was
determined after a 20-min pulse with [35S]methionine and
2 h of chase in the presence of leupeptin. These conditions
maximized the amount of I-Ad complexes that accumulate
intracellularly because of leupeptin (Amigorena et al.,
1995). As shown in Fig. 3 A, most Ii chain free I-Ad mole-
cules (immunoprecipitated using mAb MKD6) were found
in the nonshifted FFE fractions containing the bulk of cel-
lular membranes including the plasma membrane. A sec-
ond peak of class II was also detected in anodally shifted
fractions corresponding to CIIV. Little I-Ad was detected
in b-hexosaminidase–containing fractions, demonstrating
that endosomes and lysosomes were not a major site of
I-Ad accumulation after leupeptin treatment. The amounts
of labeled I-Ad–bound Ii-p10 were too low to allow detec-
tion in FFE fractions (see above). As found previously, an
unknown I-Ad–associated 12-kD protein was present at
the plasma membrane and in FFE unshifted fractions, but
this protein was not Ii chain derived (Amigorena et al.,
1995). When the cells were fractionated after a 4 h chase in
the presence of leupeptin or a 2-h chase in the absence of
leupeptin, no I-Ad was detected in any FFE-shifted frac-
tion (not shown; Amigorena et al., 1995).
To determine the distribution of the much larger quan-
tity of I-Ab Ii-p10–ab complexes that accumulated intra-
cellularly after leupeptin treatment, I-Ab–expressing A20
cells were labeled for 20 min, chased for 4 h in leupeptin,
and fractionated by FFE. As shown in Fig. 3 B, whatever
SDS-stable compact dimers (“C”) that formed despite leu-
peptin treatment were found in fractions 4–6, comigrating
with plasma membranes (indicated by alkaline phosphodi-
esterase activity; Fig. 3 C). A small fraction of these pep-
tide-loaded ab dimers was also immunoprecipitated from
endosome/lysosome-containing fractions (fractions 7–9;
b-hexosaminidase), with even less in the more anodally
Figure 4. Leupeptin treat-
ment causes MHC class II
molecules to accumulate in
lgp-containing structures by
immunofluorescence micros-
copy. Control or leupeptin-
treated (3 h, 2 mM leupeptin)
I-Ab–expressing A20 cells
were fixed, permeabilized,
and then stained for MHC
class II (FITC, using mAb
Y3P, two upper panels) vs
lgp-B (TRITC, using mAb
GL2A7, lower two panels).
In control cells, the small
amount of intracellular MHC
class II was localized to struc-
tures that were generally
negative for lgp-B. These
probably represented CIIVs
and early endosomes. Leu-
peptin treatment, however,
induced extensive colocaliza-
tion of class II and lgp-B.Brachet et al. Transport of Class II Molecules to and from Lysosomes 57
Figure 5. Selective redistribution of newly synthesized MHC
class II molecules to lysosomes in leupeptin-treated cells ana-
lyzed by Percoll gradient centrifugation. (A) Leupeptin does not
affect the density of compartments containing b-hexosaminidase
and Tfn-HRP, markers of lysosomes and endosomes, respec-
tively. After a 3-h incubation with or without 2 mM leupeptin,
cells were permitted to internalize Tfn coupled to HRP for 30
min at 378C (in the presence or absence of leupeptin) before ho-
mogenization and fractionation on Percoll density gradients. The
b-hexosaminidase and HRP activities were determined in indi-
vidual fractions. High density fractions (bottom of the gradient)
contained most of the b-hexosaminidase activity, while Tfn-HRP
was mainly present in low density fractions. No difference was
observed between leupeptin-treated and control cells. (B) Redis-
tribution of newly synthesized MHC class II molecules into high
density fractions in leupeptin-treated cells. After a pulse of
[35S]methionine and a 1-, 2-, or 4-h chase in the absence (left) or
presence (right) of leupeptin, I-Ab–expressing A20 cells were
fractionated on Percoll gradients. The membranes in each of the
gradient fractions were pelleted by centrifugation, lysed in Triton
X-100, and then immunoprecipitated using mAbs to I-Ab (Y3P).
The samples were analyzed by SDS-PAGE, and bands corre-
sponding to class II b chains were quantified by phosphorimaging
and optical densitometry. Ii-p10 intensity was also quantified af-
ter the 4-h chase in the presence of leupeptin (bottom left). Leupeptin caused a strong redistribution of class II into high density frac-
tions. The majority of Ii-p10 was also found in lysosome-containing fractions. As expected, Ii-p10 was barely detectable in control cells
and thus was not shown.The Journal of Cell Biology, Volume 137, 1997 58
shifted CIIV fractions. This was consistent with the finding
(Fig. 2) that most of the compact dimers reach the plasma
membrane rather than remaining intracellular. In contrast,
p70 (Ii-p10–ab complexes) migrated as a major peak coin-
cident with the major b-hexosaminidase-positive endo-
some/lysosome peak (Fig. 3, B and C, fractions 7–9). A
second peak was found in the nonshifted regions (fractions
3–4) typical of plasma membranes, which also contained a
minor peak of b-hexosaminidase (Fig. 3 C). Since p70 was
not detected by biotinylation at the cell surface, we suspect
that this second peak represented p70 found in residual ly-
sosomes that did not shift during the electrophoresis step.
p70 was also found trailing into the most anodally shifted
fractions characteristic of CIIV. However, unlike Ii-p10–I-
Ad class II complexes, most Ii-p10–I-Ab molecules were
not restricted to CIIV, but were found in fractions contain-
ing endosomes and lysosomes.
I-Ab ab–Ii-p10 Complexes Accumulate in Lysosomes
Using confocal microscopy, we next asked if the p70-con-
taining vesicles were of endosomal or lysosomal origin. As
expected, most of the I-Ab class II molecules detected us-
ing mAb Y3P in control cells were observed at the cell sur-
face (Fig. 4). Some intracellular staining was observed in
z40% of the class II–expressing cells, however. Intracellu-
lar class II was observed in poorly resolved vesicles in the
perinuclear region. These structures were negative for Ii
chain (not shown) and also negative for the late endo-
some/lysosome membrane marker lgp-B/lamp-2 (Fig. 4,
lower left).
After 3 h in leupeptin, the staining patterns observed
were quite different. Abundant intracellular vesicles, posi-
tive for I-Ab class II, were now observed (Fig. 4, upper right).
These class II–positive structures were also positive for
lgp-B/lamp-2 (Fig. 4, lower right). Since the anti–I-Ab
mAb used (Y3P) does not bind to class II molecules asso-
ciated with intact Ii chain, the vesicles seen by confocal mi-
croscopy are likely to represent sites of I-Ab ab–Ii-p10 ac-
cumulation in the presence of leupeptin; indeed, these
structures were also positive for Ii chain, using the mAb to
the Ii chain cytoplasmic tail IN-1 (not shown). The leupep-
tin-induced relocalization of I-Ab molecules to lgp-B/lamp-
2–positive structures was selective, since transferrin (Tfn)
receptor was not comparably redistributed as determined
by confocal microscopy (not shown) or cell fractionation
(see below).
To determine if the lgp/lamp-positive vesicles were lyso-
somes or late endosomes, we analyzed the distribution of
I-Ab class II molecules by centrifugation in 27% Percoll gra-
dients, which separate low density early and late endosomes
from heavy density lysosomes. Metabolically labeled cells
were chased for 1–4 h in the presence or absence of leu-
peptin, homogenized, and centrifuged in Percoll, and then
individual fractions were monitored for marker enzymes
and for MHC class II. As shown in Fig. 5 A, leupeptin had
no effect on the sedimentation of lysosomes (b-hexosa-
minidase) that were recovered from the same heavy den-
sity fractions in control and treated cells (left). Similarly,
conjugates of Tfn-HRP, a marker of the receptor recycling
pathway (internalized for 30 min before cell homogeniza-
tion), sedimented in the low density regions of the gradi-
ent both in the presence and absence of leupeptin (Fig.
5 A, right). Similar results were obtained for the early and
late endosomal markers rab5 and rab7, respectively (not
shown). Thus, leupeptin did not cause an overall shift of
endosomal markers to heavy density lysosomes or an al-
teration in the density properties of lysosomes themselves.
In the absence of leupeptin, I-Ab molecules were barely
detected in Percoll heavy fractions at 1–2 h of chase and
were completely absent after 4 h (Fig. 5 B, left). Thus, un-
der normal conditions, the majority of newly synthesized
class II molecules does not appear to enter lysosomes at
either short or long periods of chase. Leupeptin treatment
did, however, result in the dramatic redistribution of I-Ab
ab dimers from low density fractions (containing plasma
membranes, CIIVs, and endosomes) to the heavy density
lysosomal fractions, with .80% of the total MHC class II
being recovered from lysosomal fractions by 2–4 h of
chase (Fig. 5 B, right). More than 90% of the Ii-p10 in leu-
peptin-treated cells was also recovered by immunoprecipi-
tation from lysosomal fractions (Fig. 5 B, bottom left). No
Ii-p10 was observed in Percoll gradients of control cells.
Taken together, these results show that leupeptin causes
a progressive accumulation of newly synthesized I-Ab class
II molecules in lysosomes. The redistribution of class II is
also selective in that it is not accompanied by the lysoso-
mal accumulation of an endosomal/plasma membrane
marker (Tfn) or a second class II molecule (I-Ad; Amig-
orena et al., 1995). Given that I-Ab but not I-Ad ab dimers
formed stable complexes with Ii-p10 in the presence of
leupeptin, it seems likely that the redistribution of I-Ab
molecules reflected the accumulation of the Ii-p10–ab
complexes. Conceivably, the stable association with Ii-p10
might prevent egress of class II from lysosomes and/or
cause the missorting to lysosomes of newly synthesized
class II complexes after their arrival in endosomes. Since,
under normal conditions, the bulk of new class II does not
appear to enter lysosomes before reaching the cell surface,
it seems likely that accumulation of class II into lysosomes
after leupeptin reflects missorting in endosomes.
Characterization of Class II–positive
Lysosomal Compartments in Leupeptin-treated
Cells by Immunoelectron Microscopy
To further define the compartments where ab–Ii-p10 com-
plexes accumulated, leupeptin-treated and control cells were
analyzed by immunoelectron microscopy on ultrathin cryo-
sections. In nontreated cells, MHC class II molecules, de-
tected by the anti–mouse MHC class II mAb M5.114, were
found predominantly at the plasma membrane and very
occasionally in clathrin-coated pits. A fraction of the class
II molecules was also visualized intracellularly in tubules
and vesicles that often displayed intraluminal membranes
(Fig. 6 A). Since these vesicles were negative for lysosomal
membrane markers, they are likely to be CIIV or early en-
dosomes (see below). They were, however, strongly remi-
niscent of CIIV structures isolated from A20 cells by FFE
(Amigorena et al., 1994).
In leupeptin-treated cells, the CIIV-like structures were
also observed, but MHC class II was more often found in
compartments whose content appeared more electron
dense and replete with internal vesicles and membranesBrachet et al. Transport of Class II Molecules to and from Lysosomes 59
Figure 6. Immunogold localization of MHC class II molecules in leupeptin-treated cells. Ultrathin cryosections were immunogold la-
beled with the anti–class II mAb M5.114 and protein A–gold (PAG-10). (A) In control cells, MHC class II molecules are found on the
plasma membrane, in intracellular compartments characterized by the presence of internal membranes. (B) In leupeptin-treated cells (18-h
treatment), MHC class II molecules were detected on the plasma membrane and accumulate in electron-dense compartments displaying
internal membranes. Bars, 120 nm.The Journal of Cell Biology, Volume 137, 1997 60
(Fig. 6 B). Although these denser structures were present
in control cells, they were devoid of class II. Quantitation
of the immunolabeling revealed that, in control cells, 13%
of total class II was intracellular as compared with 43% in
leupeptin-treated cells.
We next performed double labelings for MHC class II vs
the cytoplasmic portion of Ii chain (using the IN-1 mAb),
as well as for class II vs lgp-B/lamp-2 (GLA27 mAb). Since
both antibodies were rat monoclonal IgGs and not strongly
reactive with protein A, we used a rabbit polyclonal serum
directed against the cytoplasmic domain of I-A b chain to
visualize MHC class II. The labeling of MHC class II ob-
served with the polyclonal antibody was less intense than
that obtained using M5.114. As established previously for
isolated CIIVs (Amigorena et al., 1995), CIIVs in control
cells labeled poorly with IN-1: only 23% of class II–con-
taining compartments also stained for Ii chain cytoplasmic
tail (Fig. 7 A). Similarly, the majority of these class II–con-
taining vesicles showed no or little lgp staining under nor-
mal conditions (Fig. 7 A). In contrast, after leupeptin
treatment, the number of structures containing both class
II and Ii chain, or class II and lgp-B, was greatly increased,
accounting for .70% of the total intracellular class II–
positive structures (Fig. 7, A and B). These results con-
firmed that leupeptin induced the intracellular accumula-
tion of Ii-ab complexes and illustrated the redistribution
of MHC class II molecules to lysosomes. Thus, leupeptin-
induced alterations in Ii chain cleavage would appear to
induce class II transport to lysosomes and appearance of
MIICs in cells that do not normally accumulate class II in
lysosomal compartments.
Transport of Peptide-loaded Class II Molecules from 
Lysosomes to the Cell Surface
Lysosomes are classically defined as representing the ter-
minal degradative compartment on the endocytic pathway
(Kornfeld and Mellman, 1989). This feature raises the
question of whether class II molecules present in lyso-
somes are degraded or can still be recruited to the cell sur-
face. Transport to the plasma membrane may be possible
given that MHC class II molecules are generally resistant to
degradation and that lysosomal ab dimers can be loaded
by antigenic peptide (Castellino and Germain, 1995; Qiu
et al., 1994; Rudensky et al., 1994; West et al., 1994). It has
thus far been difficult to directly monitor the degree to
which class II molecules in lysosomes survive to reach the
cell surface. Therefore, we next determined whether the
I-Ab molecules in lysosomes of leupeptin-treated cells could
reach the plasma membrane after leupeptin removal.
Cells were metabolically labeled and chased in the pres-
ence of leupeptin for 4 h to accumulate ab–Ii-p10 complexes
in lysosomes. The cells were then washed and cultured for
various periods of time in the absence of leupeptin. At
each time point, molecules reaching the cell surface were
detected by biotinylation and analyzed by SDS-PAGE
with or without boiling.
After 4 h in leupeptin, most of the I-Ab molecules were,
as expected, present as ab–Ii-p10 complexes that migrated
as 70-kD complexes (p70) when not boiled, but as mono-
meric a, b, and Ii-p10 chains after boiling (Fig. 8 A, time 0;
NB and B, respectively). Some of the class II was also
present as 60-kD peptide-loaded compact dimers (“C”)
not associated with Ii-p10. Relatively little class II was
transported to the cell surface (Fig. 8 A, time 0, righthand
panels).
After culture in the absence of leupeptin, p70 was con-
verted into compact dimers and transferred to the plasma
membrane. Surface appearance was exceedingly slow,
however, requiring up to 24 h for completion. Interest-
ingly, over this time course, relatively little (z40%) class
II was lost to degradation, a percentage not too different
from the normal rate of degradation of MHC class II in
control cells (Fig. 8 A, TOTAL, right panel). Thus, transit
to lysosomes did not accelerate the rate of class II degra-
dation but did dramatically retard its rate of surface ap-
pearance.
Figure 7. Distribution of MHC class II, Ii chain, and lgp-B in leupeptin-treated cells. (A) Quantification of MHC class II, Ii, and lgp-B in
control and leupeptin-treated cells. The quantifications were carried out on ultrathin cryosections immunogold labeled for Ii chain
(anti–Ii cytosolic tail mAb IN1) and MHC class II (rabbit anti–I-A cytoplasmic domain serum) or immunogold labeled for lgp-B (mAb
GL2A7) and MHC class II (rabbit anti–I-A cytoplasmic domain serum) or immunogold labeled for lgp-B (mAb GL2A7) and MHC
class II (rabbit anti–I-A cytoplasmic domain serum). In each case, 40 cell profiles were analyzed. (B) Immunogold localization of Ii
chain, lgp-B, and I-A in leupeptin-treated cells. (Upper panel) Ultrathin cryosections were double immunogold labeled with the Ii chain
antibody IN-1 (anti–Ii cytosolic domain; Ii CYT) and rabbit anti–I-A cytosolic tail polyclonal antibody. Ii chain accumulates in I-A–posi-
tive compartments displaying internal vesicles and electron-dense content. (Lower panel) Ultrathin cryosections were double immu-
nogold labeled with the anti–lgp-B mAb GL2A7 and rabbit anti–I-A cytosolic tail polyclonal antibody. Class II molecules were visual-
ized in electron-dense, lgp-B–positive compartments. The size of the gold particles is indicated. Bars, 120 nm.Brachet et al. Transport of Class II Molecules to and from Lysosomes 61The Journal of Cell Biology, Volume 137, 1997 62
Quantification of these results revealed a lag between
the appearance of peptide-loaded compact dimers and
their transfer to the plasma membrane (Fig. 8 B). Al-
though most of the compact dimers that formed intracellu-
larly eventually reached the cell surface, compact dimer
formation was more rapid and efficient than plasma mem-
brane appearance. Even at the start of the chase period,
significant amounts of compact dimers were already
present, none of which had reached the surface. If the time
required to reverse the effect of leupeptin was taken into
account (indicated by the rate of disappearance of p70 and
appearance of compact dimers in total cell lysates), a 3–4-h
delay was observed before newly formed compact dimers
reached the surface (Fig. 8 B). This is slow when compared
with the kinetics of transport of class II to the surface of
A20 cells in the absence of leupeptin (1–2-h lag), under
which conditions little if any newly synthesized class II
ever reaches lysosomes (Amigorena et al., 1994). How-
ever, the rate was similar to the kinetics of class II trans-
port to the surface of cells (e.g., human lymphoblasts) that
accumulate significant amounts of class II in lysosomal
compartments even in the absence of leupeptin (Neefjes
et al., 1990).
Discussion
Ii Chain Processing Controls Class II Accumulation
in Lysosomes
The Ii chain cytoplasmic domain has a well-characterized
targeting determinant that specifies the transport of MHC
class II molecules to endocytic organelles (Arneson and
Miller, 1995; Bakke and Dobberstein, 1990; Lotteau et al.,
1990; Nijenhuis et al., 1994; Odorizzi et al., 1994). The bulk
of this transport reflects direct targeting of newly synthe-
sized complexes from the TGN to endosomes, although a
fraction may reach endosomes via the plasma membrane
(Benaroch et al., 1995; Roche et al., 1993). Shortly thereaf-
ter, Ii chain is processed in a stepwise fashion, principally
by the cysteine proteases cathepsins S and B (Cresswell,
1992; Morton et al., 1995; Riese et al., 1996). In both mu-
rine and human cells, a common processing intermediate
is the 10-kD fragment Ii-p10 (Cresswell, 1996). This frag-
ment exists as a trimer complexed with three ab dimers; it
also contains the Ii chain cytoplasmic tail, membrane an-
chor, and a segment of the luminal domain probably in-
cluding the CLIP sequence thought to occupy the peptide
binding groove of ab dimers (Amigorena et al., 1995).
Although a normal intermediate, Ii-p10–ab complexes ac-
cumulate to high levels in cells treated with leupeptin
(Amigorena et al., 1995). Leupeptin thus inhibits process-
ing of Ii-p10 to yield shorter Ii chain fragments that can
dissociate from the ab dimer to permit binding of anti-
genic peptide.
Our most striking observation was that the inhibition of
Ii chain processing by leupeptin alters the postendosomal
transport of class II molecules resulting in their accumula-
tion in lysosomes, even in cells that normally transport lit-
tle class II to late endocytic compartments. We studied the
behavior of two different class II haplotypes in A20 cells,
the endogenously expressed I-Ad ab dimers as well as sta-
bly transfected cells coexpressing dimers of the I-Ab hap-
lotype. In the absence of leupeptin, both types of Ii-ab
complexes were transported through the Golgi complex
and from the TGN (presumably via endosomes) to the
plasma membrane with a lag of just 1–2 h. Cell fraction-
Figure 8. Reversal of the leupeptin block results in MHC class II transport from
lysosomes to the cell surface. (A) Reversibility of the effect of leupeptin on the in-
tracellular retention of I-Ab class II molecules. Cells were metabolically labeled for
20 min, and then chased in the continous presence of leupeptin for 4 h. Leupeptin
was then removed, and the cells were incubated for 0–24 h. After cell surface bi-
otinylation, the cells were lysed, and total (left) or surface (right) I-Ab molecules
were immunoprecipitated sequentially. Upon removal of leupeptin, the total
amount of p70 (the Ii-p10–ab complex) slowly decreased, while the amount of
peptide-loaded, SDS-stable compact dimers (“C”) increased. Ii-p10 completely
disappeared over this time course. After a lag (see B), compact dimers began to
appear at the cell surface. (B) Kinetics of compact dimer formation and transport
to the cell surface. Bands corresponding to total and surface compact dimers were
quantified by phosphorimaging. The lag between formation of compact dimers
and their subsequent appearance at the cell surface was 3–4 h.Brachet et al. Transport of Class II Molecules to and from Lysosomes 63
ation and immunocytochemistry both indicated that little
of the class II remained intracellularly and, of this, none
was detected in heavy density lysosomes. Leupeptin treat-
ment changed this distribution dramatically but selectively.
In the case of I-Ab, Ii-p10–ab complexes accumulated to
high levels, and this correlated with an almost complete in-
hibition of transport to the plasma membrane and accu-
mulation of class II in lysosomes.
The redistribution of I-Ab ab dimers to lysosomes did
not reflect a generalized effect of leupeptin treatment on
the endocytic pathway, since the inhibitor did not alter the
distribution of the early endosome marker Tfn or the dis-
tribution of lysosomal enzymes. Nor did leupeptin dramat-
ically affect the distribution of a second MHC class II hap-
lotype, I-Ad. We previously found that leupeptin caused
only a modest and transient increase in the appearance of
Ii-p10–ab complexes in cells expressing only I-Ad mole-
cules (Amigorena et al., 1995). Moreover, there was only a
minor increase in the fraction of I-Ad that reached lysosomes.
Instead, the short-lived I-Ad Ii-p10–ab complexes were
restricted to CIIV, a distinct population of endosome-related
vesicles enriched in newly synthesized MHC class II that
appear to be positioned between endosomes and the plasma
membrane (Amigorena et al., 1994; Mellman et al., 1995).
The different behaviors of the two haplotypes probably
reflected inherent differences in their abilities to form sta-
ble complexes with Ii chain intermediates. I-Ab and I-Ad
ab dimers have different affinities for CLIP, an Ii domain
thought to play a role in stabilizing the interaction be-
tween the Ii chain trimer and ab dimers (Sette et al., 1995;
Cresswell, 1996). Additionally, different class II haplo-
types can alter the efficiency of processing of bound Ii chain
(Ploegh, H., personal communication).
Although we have not established the mechanism whereby
stable association with Ii chain or Ii-p10 blocks surface
transport and triggers lysosomal accumulation, based on
our understanding of intracellular class II transport and Ii
chain processing, it is possible to suggest a plausible mech-
anism. After the delivery of new Ii chain–class II com-
plexes to endosomes, Ii chain processing would ordinarily
be expected to occur rapidly, yielding first Ii-p10 and then
CLIP. Since ab dimers bound to intact Ii chain or Ii-p10
rarely reach the plasma membrane in A20 cells, the inhibi-
tion of Ii chain processing combined with the stable associ-
ation of Ii chain (or Ii-p10) with class II would result in the
intracellular retention of the complex in endosomes. As
would be the case for almost any membrane protein pre-
vented from recycling out of endosomes, the Ii-ab or Ii-
p10–ab complexes would then be delivered to late endo-
somes and lysosomes (Mellman, 1997). Alternatively, if
newly synthesized Ii–class II complexes are transported to
the plasma membrane via lysosomes, the inhibition of Ii
chain processing induced by leupeptin might act at the
level of preventing egress from lysosomes. We were un-
able to obtain evidence in favor of this latter pathway. Re-
gardless of the actual mechanism, the most important
point is that an alteration in Ii chain cleavage results in a
dramatic relocalization of class II molecules to lysosomes.
This finding not only provides a rationale for understand-
ing postendosomal transport of class II, but also for under-
standing why different cell types exhibit significant differ-
ences in class II distribution.
Variations in class II transport may reflect important func-
tional differences among different types or different devel-
opmental stages of antigen presenting cells. For example,
we have found that immature bone marrow–derived den-
dritic cells target virtually all of their newly synthesized
class II molecules to lysosomes where they accumulate as
Ii-p10–ab complexes. When the cells are induced to ma-
ture, however, Ii-p10 is found only transiently, and new
class II molecules are efficiently delivered to the plasma
membrane (Pierre, P., S. Turley, E. Gatti, P. Webster, M.
Hull, J. Meltzer, A. Mirza, K. Inaba, R. Steinman, and I.
Mellman, manuscript submitted for publication). Conceiv-
ably, such alterations in transport might reflect the regu-
lated expression of proteases highly efficient at Ii chain
proteolysis, such as cathepsin S (Riese et al., 1996). Low
protease expression in immature cells, for example, might
result in inefficient Ii chain processing and a leupeptin-like
phenotype of class II transport to lysosomes; high expres-
sion, perhaps induced by cell differentiation, would more
efficiently cleave Ii chain, resulting in efficient cell surface
transport.
What’s in a Name? CIIVs, MIICs, Endosomes,
and Lysosomes
The nature of the endocytic compartments in which class
II molecules bind peptides has been a topic of consider-
able interest since the initial description of a heteroge-
neous but largely lysosome-like compartment containing
MHC class II, originally designated MIIC (Peters et al.,
1991). The heterogeneity of class II–containing structures
is clearly illustrated by the fact that in many murine B cell
lines, such as the A20 cell line used here, little MHC class
II is normally detected in lysosome-like structures. In-
stead, much of the intracellular class II in such cells were
found associated with a population of endosome-like struc-
tures, designated CIIV. It has been of interest to deter-
mine the structural and functional relationship between
CIIV and MIIC, and between both these structures and
conventional endosomes or lysosomes. In other words, to
what extent (if at all) do antigen presenting cells possess
specializations of the endocytic pathway? CIIV have been
physically separated from endosomes in B cells and den-
dritic cells (Amigorena et al., 1994; Pierre et al., manu-
script submitted for publication), suggesting that they rep-
resent a discrete population of vesicles. On the other hand,
MIIC have been defined as a population of class II–posi-
tive lysosomes (Peters et al., 1991, Pierre et al., 1996). Our
present results support this possibility. By treating A20
cells with leupeptin, we could “generate” a population of
vesicles morphologically and immunocytochemically simi-
lar to MIIC. Importantly, the same type of lysosomal struc-
tures rich in lgp/lamp (and HLA-DM) were also visible in
control cells before leupeptin treatment. Under these con-
ditions, however, they were largely negative for class II
molecules and thus were identified as lysosomes or late
endosomes.
MHC Class II Transport to the Plasma Membrane
Given the functional importance of HLA-DM in peptide
loading, the facts that DM is highly enriched in lysosomal
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support the probability that immunogenic peptide–class II
complexes can probably form at multiple sites intracellu-
larly, even within lysosomes (Castellino and Germain,
1995; Pierre et al., 1996; Sanderson et al., 1994). It has re-
mained unclear, however, whether class II complexes
formed in lysosomes could be efficiently recruited to the
plasma membrane, since transport from lysosomes to the
plasma membrane is thought to be a relatively rare event
(Kornfeld and Mellman, 1989). Thus, another important
observation in this paper was the direct demonstration
that lysosomal class II can reach the cell surface efficiently,
if at a slow rate.
After 4 h in leupeptin, we determined that .85% of
new I-Ab ab dimers had accumulated in lysosomes. After
an 8-h chase without leupeptin, z70% of the newly syn-
thesized cohort was detected at the cell surface by biotiny-
lation. Less than 40% of the ab dimers was lost to degra-
dation of this time course. Thus, most of the new class II
molecules that reached the surface during the 8-h chase
must have been derived from the lysosomal pool. Despite
being relatively efficient, this pathway was slow compared
with the normal kinetics of transport of class II molecules
to the cell surface in A20 cells, normally complete within 2 h
of chase. We cannot completely eliminate the possibility
that, for nonspecific reasons, leupeptin slowed a normally
rapid rate of class II transport from lysosomes to the sur-
face. However, this is unlikely in that (a) leupeptin’s inhi-
bition of SDS-stable dimer formation was reversed within
2 h of leupeptin removal; (b) the slow rate of transport is
in accord with the expectedly slow rate of lysosome to
plasma membrane transport; and (c) our pulse-chase ex-
periments did not reveal lysosomes as being a normal in-
termediate in the more rapid pathway of class II transport
seen in control cells.
Little is known about the final steps in class II transport
to the plasma membrane, and a role for CIIV in this pro-
cess is still unclear. Recent evidence has shown that, in cells
that normally localize considerable amounts of class II to
MIIC, some of the lysosomal class II reaches the surface
by direct fusion of lysosomes with the plasma membrane
(Raposo et al., 1996; Wubbolts et al., 1996). However, a
major consequence of this fusion event is the release of
class II–containing vesicles, called exosomes (Raposo et al.,
1996). In addition, some lysosomal class II may be trans-
ported in a retrograde fashion after the normal fusion of
lysosomes with incoming early or late endosomes (Mell-
man, 1997). Such retrograde delivery to endosomes might
support the “recycling” of class II molecules that had been
released from Ii chain or Ii-p10, which initially prevented
transport to the cell surface when the complexes were first
delivered to endosomes. Alternatively, lysosomes or late
endosomes may selectively bud nascent transport vesicles
containing peptide-loaded class II dimers that directly fuse
with the plasma membrane. Entry into such lysosome-
derived vesicles may be dependent on the normal process-
ing of class II–associated Ii chain.
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